Cargando…

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer

BACKGROUND: A standard of care for pretreated, advanced non–small‐cell lung cancers (NSCLCs), nivolumab has demonstrated long‐term benefit when administered for 2 years. We aimed to better discern an optimized administration duration by retrospectively analyzing real‐life long‐term efficacy in a pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geier, Margaux, Descourt, Renaud, Corre, Romain, Léveiller, Guillaume, Lamy, Régine, Goarant, Éric, Bizec, Jean‐Louis, Bernier, Cyril, Quéré, Gilles, Amrane, Karim, Gaye, Elisabeth, Lucia, François, Burte, Emilie, Chouaid, Christos, Robinet, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541160/ https://www.ncbi.nlm.nih.gov/pubmed/32412157 http://dx.doi.org/10.1002/cam4.3120

Ejemplares similares

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
por: Amrane, Karim, et al.
Publicado: (2020)

Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung
por: Agar, Camille, et al.
Publicado: (2020)

Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)
por: Renaud, Emmanuelle, et al.
Publicado: (2023)

Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases
por: Geier, Margaux, et al.
Publicado: (2021)

Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study
por: Annic, Josselin, et al.
Publicado: (2022)

Henoch–Schönlein Purpura Associated with Lung Cancer: When Paraneoplastic Manifestations Impede Oncological Management
por: Philippe, Éloïse, et al.
Publicado: (2021)

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
por: Corre, Romain, et al.
Publicado: (2018)

Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report
por: Domblides, Maël, et al.
Publicado: (2021)

Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer
por: Quéré, Gilles, et al.
Publicado: (2016)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
por: Descourt, Renaud, et al.
Publicado: (2022)

Case Report: Coronaro-bronchial fistula vascularizing a squamous cell lung cancer
por: Ntshaykolo, Chloe, et al.
Publicado: (2023)

Targeted therapy for localized non-small-cell lung cancer: a review
por: Paleiron, Nicolas, et al.
Publicado: (2016)

Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
por: Assié, Jean-Baptiste, et al.
Publicado: (2020)

Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab
por: Chouaïd, Christos, et al.
Publicado: (2022)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Lung Cancer in an Orthoprosthetist Using Vermiculite
por: Durand-Moreau, Quentin, et al.
Publicado: (2017)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
por: Monnet, Isabelle, et al.
Publicado: (2021)

Focus on treatment of lung carcinoid tumor
por: Noel-Savina, Elise, et al.
Publicado: (2013)

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
por: Nakamura, Yoshio, et al.
Publicado: (2016)

Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
por: Oya, Yuko, et al.
Publicado: (2017)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

Simulation-Based Estimates of Effectiveness and Cost-Effectiveness of Smoking Cessation in Patients with Chronic Obstructive Pulmonary Disease
por: Atsou, Kokuvi, et al.
Publicado: (2011)

Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review
por: Atsou, Kokuvi, et al.
Publicado: (2011)

Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma
por: Amrane, Karim, et al.
Publicado: (2019)

Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer
por: Tokuyama, Nagahiro, et al.
Publicado: (2021)

Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab
por: Dubus, Margaux, et al.
Publicado: (2023)

Starr–Edwards aortic valve: 50+ years and still going strong: a case report
por: Amrane, Mourad, et al.
Publicado: (2017)

Association between Age and Severity to Leptospirosis in Children
por: Guerrier, Gilles, et al.
Publicado: (2013)

Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France
por: Atsou, Kokuvi, et al.
Publicado: (2016)

Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population
por: Petrillo, Angelica, et al.
Publicado: (2020)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
por: Vergnenegre, Alain, et al.
Publicado: (2019)

Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Capillarity and wetting phenomena: drops, bubbles, pearls, waves
por: Gennes, Pierre-Gilles, et al.
Publicado: (2004)

Effect of Mechanical Pretreatments on Damage Mechanisms and Fracture Toughness in CFRP/Epoxy Joints
por: Morano, Chiara, et al.
Publicado: (2021)

A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer
por: Patel, Manish R., et al.
Publicado: (2021)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
por: Arpin, Dominique, et al.
Publicado: (2020)

False Positive 18F-FDG Positron Emission Tomography Findings in Schwannoma—A Caution for Reporting Physicians
por: Boré, Paul, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3231121v73sfqrnnoj7o05lh2t